References
- 1. Lonardo A, Adinolfi LE, Loria P et al. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. – Gastroenterology 2004, 126, 586-597.
- 2. Loria P, Marchesini G, Nascimbeni F et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. – Atherosclerosis. 232, 2014, 1, 99-109.
- 3. Adinolfi LE, Rinaldi L, Guerrera B et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. – Int J Mol Sci., 2016, 17(6).
- 4. Lonardo A, Adinolfi LE, Restivo L et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 20, 2014, 23:7089-103.
- 5. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? – Gut. 2006; 55(1):123-30.
- 6. Adinolfi LE, Restivo L, Zampino R et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. – Atherosclerosis.221, 2012, 2, 496-502.
- 7. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor? – Eur Heart J. 33, 2012, 10, 1190-2000.
- 8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med, 363, 2010, 14, 1341-50.
- 9. Defilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 227, 2013, 2, 429-36.
- 10. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60(2):392-420.
- 11. EASL (European Association for the Study of the Liver) – EASD (European Association for the Study of Diabetes) – EASO (European Association for the Study of Obesity) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402.
- 12. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 23, 2006, 5, 469-80.
- 13. WHO/IDF Report, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia, 2006.
- 14. Vanni E, Abate ML, Rizzetto M et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology. 2009 Sep;50(3):697-706.
- 15. Jonsson JR, Barrie HD, O’Rourke P et al. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 48, 2008, 1, 80-87.
- 16. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 49, 2008, 5, 831-44.
- 17. Siagris D, Christofidou M, Theocharis GJ et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat. 13, 2006, 1, 56-61.
- 18. Hsu CS, Liu CJ, Liu CH et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study. – Hepatol Int. 2, 2008, 2, 250-7.
- 19. Blaising J, Pécheur EI. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie 95, 2013; 1, 96-102.
- 20. Syed GH, Tang H, Khan M et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol. 88, 2014, 5, 2519-29.
- 21. Clark PJ, Thompson AJ, Vock DM et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology 56, 2012, 1, 49-56.
- 22. Bedossa P, Moucari R, Chelbi E et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology. 46, 2007, 2, 380-7.
- 23. Ramcharran D, Wahed AS, Conjeevaram HS et al. Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral Hepat. 18, 2011, 4, e144-52.
- 24. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 24, 2004, 12, 2219–26.
- 25. Børge G. Nordestgaard BG, Chapman MJ et al. And for the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 31, 2010, 23, 2844-2853.
- 26. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 37, 2006, 6, 1407-12.
- 27. Yang MH, Son HJ, Sung JD et al. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepato-gastroenterology 52, 2005, 66, 1832-1835.
- 28. Bozbaş H. et al. Increased lipoprotein(a) in metabolic syndrome: is it a contributing factor to premature atherosclerosis? Anadolu Kardiyol Derg. 8, 2008, 2, 111-5.
- 29. Malaguarnera M, Giugno I, Trovato BA et al. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther. 17, 1995, 4, 721-8.
- 30. Irshad M. Serum lipoprotein (a) levels in liver diseases caused by hepatitis. Indian J Med Res. 120, 2004, 6:542-5.